ABREOS BIOSCIENCES, INC.
Point-of-care lateral flow immunoassays (LFAs) for measuring monoclonal antibody drug levels and anti-drug antibodies in blood samples using proprietary peptide mimetic capture reagents (Veritopes™).
- Sector
- Medtech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2013
- Latest Form D
- $5.6M, Sep 2020
- Total capital
- $11.8M
- Federal grants
- $5.4M
- 12 awards · 2015–2020
- Rank in peer group#27 of 112
- Private capital raised
- $6.4M
- 4 Form D · last Sep 2020
- 73 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 14 pending · first 2017
- Rank in peer group#26 of 112
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$5.6M
- Federal grantHealth and Human S · Phase II · Personalized precision dosing of anti-TNF biologic therapies$841K
- Federal grantHealth and Human S · Phase II · Personalized precision dosing of biologic therapies in oncology$1K
- Federal grantHealth and Human S · Phase II · Personalized precision dosing of anti-TNF biologic therapies$741K
- Federal grantHealth and Human S · Phase II · Personalized precision dosing of biologic therapies in oncology$720K
- Federal grantHealth and Human S · Phase I · Affinity Purification of Biologics with Mimetope Peptides$218K
- Federal grantHealth and Human S · Phase II · Personalized precision dosing of anti-TNF biologic therapies$299K
- Private capital raisedForm D · SEC · 3rd filing$150K
- Private capital raisedForm D · SEC · 2nd filing$475K
- Private capital raisedForm D · SEC · 1st filing$175K
Show 6 earlier federal awards
- Federal grantHealth and Human S · Phase II · Personalized precision dosing of biologic therapies in oncology$1.5M
- Federal grantHealth and Human S · Phase I · Novel Materials for Viral Purification$224K
- Federal grantHealth and Human S · Phase I · Activin A antagonist for treatment of cancer-associated cachexia$225K
- Federal grantHealth and Human S · Phase I · Novel Activin A Antagonists for Treatment of Osteoporosis$225K
- Federal grantHealth and Human S · Phase I · Cleavage Coupled Lateral Flow Immunoassay for Rapid Endotoxin Testing$214K
- Federal grantHealth and Human S · Phase I · Multiplexed DeNAno Protein Assay and Quantitation: Sequencing Based Proteomics$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
2months
from ABREOS BIOSCIENCES, INC.’s first federal award to its first private round.
- First federal award · Jan 2015
- Health and Human S · $225K
- First Form D · Mar 2015
- $175K · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grants#27 · top 24%
- Granted patents#26 · top 23%
- Linked publications#11 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Bradley MessmerResearcherExecutive Officer, DirectorLinked by 1 patent · $5.2M in grants as PI
- Neil SenturiaDirectorNamed in SEC Form D filings
- Peter HaberzDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 16- PendingMethods and Compositions For Measuring Serum Analyte Levels From Biological MatricesUSPTOApplication 18840249
- PendingDetection And Quantification Of NatalizumabUSPTOApplication 18404461
- PendingDetection And Quantification Of NatalizumabUSPTOApplication 18312915
Show all 16 patent records
- Methods and Compositions For Measuring Serum Analyte Levels From Biological MatricesMay 22, 2025 · Application 18840249Pending
- Detection And Quantification Of NatalizumabAug 8, 2024 · Application 18404461Pending
- Detection And Quantification Of NatalizumabDec 28, 2023 · Application 18312915Pending
- Detection And Quantification Of NatalizumabJun 20, 2023 · US 11,680,948Granted
- Immunoaffinity Purification Of Antibodies Using MimetopesOct 11, 2018 · Application 15944099Pending
- Point-of-care Diagnostic DeviceOct 24, 2017 · US D,800,912Granted
- Lateral Flow ImmunoassayOct 15, 2015 · Application 14686578Pending
- Cleavage Coupled Competitive Lateral Flow AssayApplication PCTUS2016014924Pending
- Lateral Flow ImmunoassayApplication PCTUS2015025796Pending
- Cleavage Coupled Competitive Lateral Flow AssayApplication 62108029Pending
- Methods And Compositions For Measuring Serum Analyte Levels From Biological MatricesApplication PCTUS2023063591Pending
- Methods And Compositions For Measuring Serum Analyte Levels From Biological MatricesApplication 63315935Pending
- Immunoaffinity Purification Of Antibodies Using MimetopesApplication PCTUS2018025889Pending
- Detection And Quantification Of NatalizumabApplication PCTUS2017046499Pending
- Immunoaffinity Purification Of Antibodies Using MimetopesApplication 62481282Pending
- Detection And Quantification Of NatalizumabApplication 62374217Pending
Recent research by its founders
- Intact natalizumab pharmacokinetics is impacted by endogenous IgG4 concentration20241 cites
- Accurate Prediction of Serum Antibody Levels from Noninvasive Saliva/Nasal Samples20235 cites
- Peptide Mimotope-Enabled Quantification of Natalizumab Arm Exchange During Multiple Sclerosis Treatment20223 cites
Related companies, and why
- VASOPTIC MEDICAL, INC.Similar federal contract value in Medtech · null in contracts
- Nupulsecv IncSimilar federal contract value in Medtech · null in contracts
- VADOVATIONS, INC.Similar federal contract value in Medtech · null in contracts
- SENAPTEC INC.Similar federal contract value in Medtech · null in contracts
- NXT BIOMEDICAL, LLCSimilar federal contract value in Medtech · null in contracts
- BIVACOR INCSimilar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .